ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.…
ImmuCell Q3 Earnings Rebound as Sales Surge and Margins Expand Y/Y
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026
ImmuCell (NASDAQ: ICCC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 73 employees.
The shares were at 10.92 USD on 20 November 2026, up 79.0% over 52 weeks. Its 52-week range is 4.520 USD to 12.10 USD: the price is 9.8% below the high and 141.6% above the low.
At a market capitalisation of 99.28M USD, it trades at 57.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 73% for ICCC.
ImmuCell reports return on equity of -3.8%, an operating margin of 16.9% and revenue up 46.0% year over year.
Its debt exceeds its cash by 4.10M USD, a debt-to-equity ratio of 0.49. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. The next earnings report is expected on 3 March 2027.